Pfizer's ketohexokinase inhibitor decreases liver fat content in NAFLD Phase II

As Pfizer considers which combination therapies to develop for NASH, the pharma reported that its KHK inhibitor, PF-06835919, as monotherapy reduced whole liver fat in a Phase II trial to treat non-alcoholic fatty liver disease.

Among 48 evaluable patients with NAFLD, once-daily 300 mg PF-06835919 significantly reduced whole liver fat as measured by MRI proton density fat fraction (MRI-PDFF) from baseline to week six by 26.5% vs. 7.78% for placebo, meeting the primary endpoint (p<0.0395). The data were released in an abstract ahead of the European Association for the Study of the Liver meeting in Vienna...